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Abstract
Background: Exosomes are involved in intercellular communication. The aim of this study was to investigate whether
circulating exosomes effectively contribute to the inflammatory response in systemic lupus erythematosus (SLE).
Methods: Exosomes were purified from SLE patients and healthy controls (HCs). Healthy peripheral blood
mononuclear cells (PBMCs) were stimulated with exosomes isolated from SLE patients and HCs in the presence or
absence of Toll-like receptor (TLR) inhibitors. Production of interferon (IFN)-α, tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, and IL-6 were measured. Correlation between exosome levels and SLE disease activity was examined.
Results: The serum exosomes levels were significantly higher in SLE patients than in HCs. SLE exosomes induced a
higher production of IFN-α, TNF-α, IL-1β, and IL-6 compared to healthy exosomes. SLE serum that was depleted of
exosomes and SLE exosomes that were mechanically disrupted failed to induce any significant cytokine production.
Exosome-mediated production of TNF-α, IL-1β, and IL-6 was decreased by the TLR4 antagonist, whereas that of IFN-α
was suppressed by the TLR1/2, TLR7, and TLR9 antagonists. Exosome levels correlated with disease activity in SLE
patients (rho = 0.846, p = 0.008).
Conclusions: The circulating exosomes are immunologically active and their levels correlate with disease activity in
SLE patients. The circulating exosomes might serve as novel biomarkers of SLE disease activity.
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Background
Effective communication between immune cells is critical
for a coordinated immune response. In systemic lupus
erythematosus (SLE), the dysfunctional communication
leads to abnormal activation of immune cells, autoanti-
body production, complement activation, and tissue
inflammation that ultimately damages multiple organs
[1]. In addition to cytokines such as tumor necrosis fac-
tor (TNF)-α, interferons (IFNs), and interleukins (ILs),
acellular microvesicles, delimited by a lipid bilayer, have
been postulated as effective mediators of intercellular
communication in both physiologic and pathologic situa-
tions [2]. Exosomes are extracellular vesicles, 50–100 nm
in diameter, which originate from the multivesicular bodies
of endosomes. They carry intergrins and tetraspanins such
as CD63 and CD81 on their surface [3, 4]. Although the
primary role of exosome production is thought to be the
removal of unwanted cellular components, those compo-
nents on and within exosomes can exert diverse biological
functions depending on the cells of origin [5–8]. Exosomes
are believed to contain molecules that can induce a pro-
inflammatory response via pattern-associated molecular
patterns (PAMP) receptors such as Toll-like receptors
(TLRs). TLRs are a family of receptors through which
the mammalian innate immune cells recognize invading
pathogens to mount a proper immune response [9].
TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface,
whereas TLRs 3, 7, 8, and 9 are located in intracellular
endosomes [10, 11]. Recently microRNAs (miRNAs) in
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the exosomes, which are released from cancer cells, have
been shown to induce inflammatory responses via TLRs
and to promote cancer metastasis [12].
Microparticles derived from SLE patients have been
shown to have a higher concentration of immunoglobulins
and complement components at the expense of cytoskel-
etal proteins as compared to those derived from healthy
controls (HCs) [10, 11]. Accordingly, the inflammatory
process of SLE might produce “SLE-specific” exosomes
that might, in return, amplify the abnormal immune re-
sponse. The aim of the current study was to investigate
whether SLE exosomes are able to mount a significant in-
flammatory response and whether the levels of circulating
exosomes correlate with SLE disease activity.
Methods
Patients
HCs (n = 8), and patients with SLE (n = 19) were enrolled
after obtaining informed consent (Additional file 1:
Table S1). The patients fulfilled the American College of
Rheumatology revised criteria for the classification of SLE
[13]. SLE disease activity index 2000 (SLEDAI-2K) was
determined at the time of blood sampling [14].
Exosome isolation and quantification
Serum was prepared from fresh peripheral blood by cen-
trifugation. Exosomes were purified from serum using
ExoQuick (System Biosciences, CA, USA) according to
the manufacturer’s instructions. Briefly, 63 μL ExoQuick
solution was added to 250 μL serum. After 30 min at 4 °C,
exosomes were pelleted using centrifugation at 1500 g
for 30 min. The pellets containing exosomes were resus-
pended in 50 μL sterile water.
Exosomes were quantified using EXOCET Exosome
Quantification Assay Kit and ELISA of exosome surface
markers (EXOEL-CD63A-1 and EXOEL-CD81A-1; Sys-
tem Biosciences) according to the manufacturer’s instruc-
tions. Of note, EXOCET measures enzymatic activity of
acetylcholinesterases (AChE), which are enriched within
exosomes. EXOEL-CD63A-1 and EXOEL-CD81A-1 are
a direct enzyme-linked immunosorbent assay (ELISA)-
based method to quantify CD63 and CD81.
Exosome disruption
Exosomes were mechanically disrupted using ultra-
sonication (Bioruptor, BMS Co., USA) for 15 min (10 s
sonication and 30 s cooling cycle) on ice.
Transmission electron microscopy (TEM)
Exosomes were dried onto a copper grid with a lacey
carbon film. The grid was negatively stained with 2 %
uranyl acetate and imaged with a Carl Zeiss LIBRA120
(Carl Zeiss, Oberkochen, Germany) with an accelerating
voltage set to 120 kV. Images were taken with a Orius
SC200W 2 CCD camera (Gatan Inc., CA, USA).
Stimulation of immune cells with exosomes
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinzed peripheral venous blood of HCs by
density gradient centrifugation using Ficoll-paque plus
gradient (GE Healthcare Biosciences, Uppsala, Sweden).
Cell viability was assessed with trypan blue dye exclusion.
PBMCs (5 × 106 cells/mL) were stimulated with 10 μL
purified exosomes in RPMI-1640 supplemented with 100
U/mL penicillin and 100 μL/mL streptomycin for 24 h at
37 °C in a 5 % CO2 incubator.
To investigate the involvement of TLRs, PBMCs
were pretreated with TLR1/2 antagonist (CU-CPT22;
Calbiochem, MA, USA), TLR4 antagonist (LPS-RS ultra-
pure; Invivogen, CA, USA), TLR7 antagonist (ODN20958;
Invivogen, CA, USA), or TLR9 antagonist (ODN2088;
Invivogen, CA, USA) for 1 h. Then the cells were incu-
bated with exosomes for 24 h. Following stimulation,
levels of IFN-α, TNF-α, IL-1β, and IL-6 in the superna-
tants were measured using ELISA according to the manu-
facturers’ instructions (IFN-α, PBL Assay Science, NJ,
USA; TNF-α, IL-1β, and IL-6, BD Biosciences, CA, USA).
Exosome uptake by cells
The purified exosomes were labeled with carboxyfluores-
cein succinimidyl diacetate ester (CFSE) using Exo-Glow
kits (System Biosciences, CA, USA) according to the man-
ufacturer’s instructions. PBMCs were incubated with the
CFSE-labeled exosomes. After the indicated time points,
PBMCs were stained and analyzed using FACSCalibur
flow cytometer and Cellquest software (BD Biosciences).
For the confocal microscopy, PBMCs were treated
with the CFSE-labeled exosomes and then stained with
LysoTracker red DND-99 (Life Technologies, MA,
USA), which marks endosomes. After cover-slipping
with Fluoroshield with DAPI (ImmunoBioScience, WA,
USA), the cells were imaged using a Leica TCS SP8
(Leica, Wetzlar, Germany).
For co-localization of exosomes and TLRs, PBMCs
were treated with the CFSE-labeled exosomes and then
were fixed in 4 % paraformaldehyde (Sigma, MO, USA) in
phosphate-buffered saline (PBS). After washing, PBMCs
were stained with antibodies against TLR2 (TL2.1, mouse
monoclonal), TLR4 (HTA125, mouse monoclonal), TLR7
(4G6, mouse monoclonal), or TLR9 (26C593.2, mouse
monoclonal). Of note, for TLR7 and TLR9 staining, the
cells were permeabilized with 0.1 % triton X-100 (Sigma)
prior to incubation with primary antibodies. All TLR
antibodies were purchased from Life Technologies (MA,
USA). Alexa Fluor 488 goat anti-mouse IgG (Molecular
Probes, CA, USA) was applied in PBS containing 10 % fetal
bovine serum (FBS). After cover-slipping with Fluoroshield
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with DAPI (ImmunoBioScience), co-localization of
exosomes and TLRs were imaged using a Leica TCS
SP8 (Leica).
Statistical analyses
Differences between two groups were assessed by Mann-
Whitney U tests or Wilcoxon matched-pairs signed rank
test, as appropriate. The correlations between SLEDAI
and cytokine production were examined using Spearman
correlation. All reported p values were two-sided. P < 0.05
was considered to indicate statistical significance. All
statistical analyses were performed using GraphPad
Prism 5.01 (GraphPad Software Inc., CA, USA).
Results
Exosomes are enriched in serum of SLE patients
The purified exosomes were visualized using TEM as
shown in Fig. 1a. They were 50–100 nm in size. Since
exosomes are rich in AChE [15, 16], CD63, and CD81
[17, 18], their levels can be used to estimate the number
of exosome particles. Based on AChE assay, the serum
levels of exosomes were significantly higher in SLE
patients (n =13) than in HCs (n = 8) (median with inter-
quartile range (IQR), μL: 43.10 × 107 (9.61 × 107–58.44 ×
107) vs. 10.07 × 107 (5.36 × 107–13.01 × 107), respectively;
p = 0.023) (Fig. 1b). CD81 levels were significantly higher
in SLE exosomes (n = 9) than HC exosomes (n = 6)
(median (IQR), μL: 40.80 × 107 (6.01 × 107–44.00 × 107)
vs. 5.30 × 107 (4.14 × 107–7.68 × 107), respectively; p =
0.008) (Fig. 1c).
Similarly, CD63 levels were higher in SLE exosomes (n =
9) than HC exosomes (n = 6) (median (IQR), μL: 40.15 ×
107 (28.41 × 107–55.29 × 107) vs. 24.45 × 107 (18.29 × 107–
41.30 × 107), respectively; p = 0.013) (Fig. 1d). Taken to-
gether, the serum levels of circulating exosomes were
significantly higher in SLE patients than in HCs.
SLE exosomes induces stronger cytokine production
PBMCs (5 × 105 cells) from other additional healthy do-
nors were treated with 10 μL of exosomes purified from
HCs (n = 5) or SLE patients (n = 10). As compared to the
HC exosomes, the SLE exosomes induced PBMCs to pro-
duce significantly more IFN-α (median (IQR), pg/mL: 0.00
(0.00–0.00) vs. 22.34 (0.00–120.9), respectively; p = 0.004),
TNF-α (median (IQR), pg/mL: 0.00 (0.00–5.00) vs. 97.47
(53.17–294.9), respectively; p = 0.023), IL-1β (median
(IQR), pg/mL: 7.10 (0.00–44.52) vs. 97.24 (40.20–215.2),
respectively; p = 0.013), and IL-6 (median (IQR), pg/mL:
1259 (802.5–1669) vs. 3596 (1790–7352), respectively;
p = 0.002) (Fig. 2a).
Next, PBMCs (5 × 105 cells) were stimulated with fixed
numbers of exosomes (5.2 × 109 exosomes). Higher IFN-α
production was induced by the SLE exosomes than the
HC exosomes (median (IQR), pg/mL: 26.83 (1.72–63.68)
vs. 0.00 (0.00–0.00), respectively; p = 0.005). Even when
PBMCs (5 × 105 cells) were treated with up to a 10-fold
Fig. 1 Enriched exosomes in SLE. a The size and shape of purified exosomes were evaluated by TEM imaging. The exosomes were 50–100 nm in
size (arrows) and had a lipid layer (insert). b Systemic lupus erythematosus (SLE) patients had higher serum levels of exosomes than healthy controls
(HCs) by acetylcholinesterase (AChE) assay. Both exosome protein markers CD81 (c) and CD63 (d) were higher in SLE than in HC. Data are presented
as the median and interquartile range. *p < 0.05, **p < 0.01
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higher amount of exosomes from HCs (5.2 × 1010 exo-
somes), production of IFN-α was not detected. TNF-α
induction tended to be higher by the SLE exosomes
than the HC exosomes (median (IQR), pg/mL: 26.83
(15.73–76.70) vs. 8.18 (6.53–17.09), respectively; p =
0.056), whereas IL-1β and IL-6 production did not dif-
fer between them (Additional file 2: Figure S1).
To test whether the structural integrity of exosomes is
important for the immune response, the SLE exosomes
were physically disrupted by ultra-sonication. The dis-
rupted SLE exosomes significantly lost the ability to
induce cytokine production. Similarly, SLE serum that
was depleted of exosomes failed to induce a significant
cytokine production either (Fig. 2b).
To assess the possibility of disease-specific effects of
SLE exosomes, healthy PBMCs (5 × 105 cells) were treated
with 10 μL of exosomes purified from HCs (n = 8),
rheumatoid arthritis (RA; n = 8) or SLE patients (n = 8).
As compared to the RA exosomes, the SLE exosomes
induced PBMCs to produce significantly more IFN-α (me-
dian (IQR), pg/mL: 1.84 (0.00–6.07) vs. 22.39 (6.32–
55.89), respectively; p = 0.013) and TNF-α (median (IQR),
pg/mL: 276.2 (188.4–393.0) vs. 1096 (745.3–1396),
respectively; p = 0.001). IL-6 production did not differ
between RA and SLE exosomes (median (IQR), pg/mL:
10331 (9421–10,906) vs. 9097 (6110–13,024), respectively;
p = 0.556) (Fig. 3).
SLE exosomes induce cytokine production in a
TLR-dependent manner
We investigated whether circulating SLE exosomes are
engulfed by immune cells. PBMCs were incubated with
CFSE-labeled SLE exosomes. After 2 h, the exosomes
were observed on the surface and in endosomes of
PBMCs (Fig. 4a). The labeled exosomes were visible as
early as 30 min after incubation and the exosome uptake
increased with time; after 2 h, 88.2 ± 10.0 % cells engulfed
the exosomes (Fig. 4b).
Next, we tested whether exosomes bind specifically to
TLRs on the cell surface and/or reach intercellular TLRs.
The exosomes co-localized with TLR2, TLR4, TLR7, and
TLR9 (Fig. 4c), suggesting that cytokine production
might be mediated in a TLR-dependent manner. Indeed,
production of TNF-α, IL-1β, and IL-6 was profoundly
Fig. 2 Cytokine production by exosomes. a Healthy PBMCs were stimulated with exosomes from healthy controls (HC) and systemic lupus
erythematosus (SLE) patients, and production of IFN-α, TNF-α, IL-1β, and IL-6 were measured. Data are presented as the median and interquartile
range. b Cytokine production by SLE exosomes that were mechanically disrupted and SLE serum that was depleted of exosomes relative to SLE
exosomes were compared. Data are presented as the median and interquartile range. *p < 0.05, **p < 0.01. IFN interferon, IL interleukin, TNF tumor
necrosis factor
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decreased in the presence of the TLR4 antagonist, whereas
the production of IFN-α was blocked by the TLR1/2,
TLR7, and TLR9 antagonists (Fig. 5).
Serum exosome levels correlate with SLE disease activity
We investigated whether higher SLE disease activity was
associated with increased exosome levels and proinflam-
matory cytokine production. The serum exosome levels
based on AChE assay significantly correlated with SLE
disease activity (Spearman rho = 0.846, p = 0.008). In
addition, production of IFN-α, TNF-α, IL-1β, and IL-6
by SLE exosomes correlated significantly with SLE disease
activity (Fig. 6).
Discussion
SLE is a systemic autoimmune disease that leads to local
and systemic inflammation and damage in multiple or-
gans [19]. Intercellular communication is of paramount
importance for both the normal and abnormal immune
response. In the current study, we identified exosomes as
potential intercellular messengers to promote inflamma-
tory response in SLE; SLE exosomes were able to elicit a
Fig. 3 Comparison between cytokine production by rheumatoid arthritis and systemic lupus erythematosus. Production of IFN-α (a), TNF-α (b),
and IL-6 (c) by the healthy PBMCs after stimulation with exosomes from healthy controls (HC; n = 8), rheumatoid arthritis (RA; n = 8) or systemic
lupus erythematosus (SLE; n = 8) patients were measured. Data are presented as the median and interquartile range. *p < 0.05, **p < 0.01, ***p < 0.0001.
IFN interferon, IL interleukin, NS not significant, TNF tumor necrosis factor
Fig. 4 Exosomes from SLE induce secretion of inflammatory cytokines via Toll-like receptors (TLRs). a Human PBMCs were incubated with
carboxyfluorescein succinimidyl diacetate ester (CFSE)-labeled SLE exosomes. Confocal images showed that exosomes (green) co-localized
with endosomes (yellow in the merged images). Nucleus (Hoechst blue), endosome (red). b PBMCs (n = 3) were treated with CFSE-labeled
SLE exosomes. The percentage of exosome (+) PBMCs increased with time. c PBMCs were stained with Hoechst for nucleus (blue) and anti-TLR
antibodies (red). The exosomes (green) co-localized with TLRs (yellow in the merged images). Scale bars = 10 μm
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significant inflammatory response in a TLR-dependent
manner, and the levels of circulating exosomes correlated
with disease activity of SLE.
Apoptotic cells in inflamed tissues might release more
exosomes into the blood since proper clearance of cell
debris is compromised in SLE [20, 21]. Those exosomes
can reach and activate immune cells at remote sites via
blood circulation. Indeed, increased levels of exosomal
miRNA in the urine of patients with active lupus nephritis
suggest that inflamed organ or tissue can serve as an im-
portant source of exosome production [22]. Therefore, the
levels and composition of circulating exosomes in SLE pa-
tients might be associated with SLE disease activity.
In the current study, the circulating exosomes from
SLE patients were proinflammatory; they were able to
induce healthy PBMCs to produce inflammatory cyto-
kines (Fig. 2a). In addition, IFN-α and TNF-α production
by a fixed number of exosome particles was higher for the
SLE exosomes than the HC exosomes, while IL-6 produc-
tion per exosome particle did not differ between them
(Additional file 2: Figure. S1). Strikingly, exosomes from
patients with RA were able to induce IL-6 production but
not IFN-α production (Fig. 3). The difference between RA
and SLE exosomes in regard to IFN-α production is of
particular interest, since type 1 interferon has been postu-
lated as a key cytokine in SLE but not in RA [23–25]. One
might speculate that the composition and biologic effects
of exosomes are disease-specific. This is supported by the
finding that microparticles from patients with active SLE
have higher levels of immunoglobulins and complement
factors at the expense of the structural proteins [11]. It
remains to be defined whether the exosomes carry the
disease-specific “molecular signature”, such as the “syn-
ovial signature” in RA or “kidney signature” in SLE.
It is striking that the exosomes lost their biological ef-
fect when their microvesicular structure was physically
disrupted (Fig. 2b). This suggests that not only the amount
and composition but also the structural integrity are crucial
for their biologic function. Since the cross-linking of recep-
tors on target cells is a common initial step in cell activa-
tion, the activating molecules on the exosomes, wrapped
spatially tightly together, might better cross-link the recep-
tors on the target cells than in their free form. The mem-
brane structure might allow exosomes to be better engulfed
by target cells and so reach intracellular receptors. Indeed,
the exosomes from SLE patients were able to induce IFN-α
that is mainly triggered by activation of the intracellular
endosomal TLR7 and TLR9 [26]. Our findings show that
the circulating SLE exosomes can bind to and activate both
surface and endosomal TLRs, leading to TLR-mediated
proinflammatory cytokine secretion (Fig. 4). Since the
blockade of TLR with specific antagonists inhibited the
cytokine production, the SLE exosomes exert their biologic
function, at least in part, in a TLR-dependent fashion.
Fig. 5 Exosomes from SLE induce secretion of inflammatory cytokines via Toll-like receptors (TLRs). Human PBMCs were incubated with SLE exosomes
in the presence of specific antagonists to TLR1/2, TLR4, TLR7, and TLR9. After 24 h, levels of IFN-α (a), TNF-α (b), IL-1β (c), and IL-6 (d) were determined.
Data are presented as the median and interquartile range.*p < 0.05. IFN interferon, IL interleukin, TNF tumor necrosis factor
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The disease activity correlated significantly with the
levels of circulating exosomes and their proinflamma-
tory potential, implying that a higher disease activity is
associated with both quantitative and qualitative
changes in produced SLE exosomes (Fig. 6). Whether
the increased exosome production is a cause or result
of the increased SLE activity, or both, needs further in-
vestigation. Taken together, exosomes in SLE are effect-
ive intercellular messengers and possibly contribute to
the pathologic immune response [22]. Given the strong
immune stimulatory effect of exosomes, removal of the
circulating exosomes might offer a novel therapeutic
approach in SLE.
The current report has several limitations that might
ignite interest for further investigations. First, the cellu-
lar source of the circulating exosomes and mechanisms
by which exosomes induce inflammatory cytokine pro-
duction in patients with active SLE need to be defined.
Second, the molecules in exosomes that activate the
TLRs need to be identified. By characterizing the pro-
teins and DNA/RNA in the SLE exosomes using mass
spectrometry and miRNA microarray, the cellular origin
of the exosomes could be indirectly identified. Third,
since SLE patients with higher SLEDAI received more
intense medical treatment, the effects of the concomitant
medications on the exosome production and function
need to be further examined. Last but not the least, a
prospective study with a large sample size is needed to
address whether or not the amount and function of
exosomes change over time with SLE treatment.
Conclusions
The circulating exosomes are immunologically active and
their levels correlate with disease activity in SLE patients.
The circulating exosomes might serve as novel biomarkers
of SLE disease activity.
Fig. 6 Correlation between SLE disease activity and cytokine production by exosomes. a Serum exosome levels correlated significantly with SLE
disease activity index 2K (SLEDAI) in nine patients with SLE. Production of IFN-α (b), TNF-α (c), IL-1β (d), and IL-6 (e) by the healthy PBMCs after
stimulation with SLE exosomes (n = 8) correlated with SLEDAI. P values were generated by using Spearman correlation. IFN interferon, IL interleukin,
TNF tumor necrosis factor
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Additional files
Additional file 1: Table S1. Demographic and clinical characteristics of
the SLE patients. (DOCX 16 kb)
Additional file 2: Figure S1. Cytokine production by fixed number of
exosomes. IFN-α (A), TNF-α (B), IL-1β (C), and IL-6 (D) production by the
healthy PBMCs after stimulation with a fixed number of exosomes from
healthy controls (HC) or systemic lupus erythematosus (SLE) patients
were measured. Data are presented as the median and interquartile
range. (PDF 87 kb)
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